Switching to systemic therapy after locoregional treatment failure: Definition and best timing

Published on Jan 15, 2020in Clinical and molecular hepatology
· DOI :10.3350/CMH.2019.0021N
Sadahisa Ogasawara18
Estimated H-index: 18
(Chiba University),
Yoshihiko Ooka16
Estimated H-index: 16
(Chiba University)
+ 16 AuthorsNaoya Kato42
Estimated H-index: 42
In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE). Before sorafenib came into wide use, TACE had been pointlessly carried out repeatedly. It was in the early 2010s that the concept of TACE refractory was advocated. Two retrospective studies from Japan indicated that conversion from TACE to sorafenib the day after patients were deemed as TACE refractory improved overall survival compared with continued TACE, according to the definition by the Japan Society of Hepatology. Nowadays, phase 3 trials have shown clinical benefits of several novel molecular target agents. Compared with the era of sorafenib, sequential treatments with these molecular target agents have gradually prolonged patients' survival and have become major strategies in patients with HCC. Taking these together, conversion from TACE to systemic therapies at the time of TACE refractory, compared with before, may have a greater impact on survival and may be considered deeper in the decisions-making process in patients with unresectable HCC who are candidate for TACE. Up-to-date information on the concept of TACE refractory is summarized in this review. We believe that the survival of patients with unresectable HCC without both macrovascular invasion and extrahepatic metastasis may be dramatically improved by optimal timing of TACE refractory and switching to systemic therapies.
  • References (55)
  • Citations (0)
📖 Papers frequently viewed together
11 Citations
11 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Sadahisa Ogasawara (Chiba University)H-Index: 18
#2Yoshihiko Ooka (Chiba University)H-Index: 16
Last. Naoya Kato (Chiba University)H-Index: 13
view all 32 authors...
Background Conversion from sorafenib to regorafenib is primarily an evidence-based treatment strategy in patients with advanced hepatocellular carcinoma (HCC). This study aimed to assess the safety and efficacy of sequential therapy with sorafenib and regorafenib in patients with advanced HCC by analysis of outcomes in clinical practice with the aim to complement phase III findings. Methods The medical records of patients with advanced HCC receiving regorafenib were retrieved to collect data on ...
5 CitationsSource
#1N. KokudoH-Index: 70
#2Nobuyuki TakemuraH-Index: 9
Last. Yutaka MatsuyamaH-Index: 41
view all 21 authors...
: The fourth version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development, and Evaluation system, which was published in October 2017 in Japanese. New or revised recommendations were described, herein, with a special reference to the surveillance, diagnostic, and treatment algorithms.
13 CitationsSource
#1Rebecca A. Miksad (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 3
#1Rebecca A. Miksad (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 23
Last. Fabio Piscaglia (UNIBO: University of Bologna)H-Index: 55
view all 5 authors...
The real-world incidence of chronic liver damage after transarterial chemoembolization (TACE) is unclear. LiverT, a retrospective, observational study, assessed liver function deterioration after a single TACE in real-world hepatocellular carcinoma (HCC) patients in US practice. Eligible HCC patients identified from Optum’s integrated database using standard codes as having had an index TACE between 2010 and 2016 with no additional oncologic therapy in the subsequent 3 months. At least one labor...
3 CitationsSource
#1MasatoshiKudoH-Index: 78
#2Kazuomi UeshimaH-Index: 28
Last. Naoshi NishidaH-Index: 29
view all 20 authors...
Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous disease that includes a subgroup of patients who do not benefit from TACE. The treatment strategy for this subgroup of patients currently remains an unmet need in clinical practice. Here, we performed a proof-of-concept study that lenvatinib may be a more favorable treatment option over TACE as an initial treatment in intermediate...
#1Lauranne Piron (University of Montpellier)H-Index: 1
#2Julien Le RoyH-Index: 3
Last. Boris Guiu (University of Montpellier)H-Index: 30
view all 10 authors...
Introduction Cone-beam computed tomography (CBCT) has been developed to improve reliability of many interventional radiology (IR) procedures performed with Angio system, such as transarterial chemoembolization (TACE). Angio-CT has emerged as a new imaging technology that combines a CT scanner with an Angio system in the same IR suite. The purpose of our study was to compare Angio system with CBCT capability and Angio-CT in terms of patient radiation exposure during TACE procedures.
#1Changhoon Yoo (UOU: University of Ulsan)H-Index: 17
#2Joong Won ParkH-Index: 23
Last. Ho Yeong Lim (SKKU: Sungkyunkwan University)H-Index: 28
view all 9 authors...
Background The pivotal RESORCE trial showed that regorafenib was effective as second-line therapy for patients with advanced HCC who progressed on first-line sorafenib. Real-world data are needed to assess clinical outcomes and adverse events in the setting of daily practice. Methods Between April 2017 and August 2017, the Named Patient Program (NPP) was activated to provide controlled, pre-approval access of regorafenib in Korea. This analysis is a multicenter retrospective study of patients wh...
2 CitationsSource
#1Yuji EsoH-Index: 9
#2Atsushi TakaiH-Index: 12
Last. Hiroshi SenoH-Index: 34
view all 7 authors...
Transarterial chemoembolization (TACE) is the recommended first-line treatment for intermediate-stage hepatocellular carcinoma (HCC). In patients who became refractory to TACE, a treatment switch to tyrosine kinase inhibitors (TKIs) needs to be considered. However, TACE could worsen liver function, thereby narrowing the time window for a switch to TKIs because TKIs are recommended for patients with Child-Pugh grade A (CP-A). We investigated the factors associated with CP grade deterioration afte...
#1Jean-Luc RaoulH-Index: 55
#2Alejandro Forner (University of Barcelona)H-Index: 30
Last. Thierry de BaereH-Index: 1
view all 6 authors...
Abstract Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate stage HCC, including those with l...
6 CitationsSource
#1Joong Won ParkH-Index: 23
#2Jeong Seop LeeH-Index: 25
Last. Won Il JangH-Index: 10
view all 43 authors...
29 CitationsSource
#1Freddie Ian Bray (IARC: International Agency for Research on Cancer)H-Index: 91
#2Jacques Ferlay (IARC: International Agency for Research on Cancer)H-Index: 65
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 110
view all 6 authors...
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer...
3,723 CitationsSource
Cited By0